Research Progress of Metal Anticancer Drugs
Cancer treatments, including traditional chemotherapy, have failed to cure human malignancies. The main reasons for the failure of these treatments are the inevitable drug resistance and serious side effects. In clinical treatment, only 5 percent of the 50 percent of cancer patients who are able to...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-12-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/15/12/2750 |
| _version_ | 1797379625533308928 |
|---|---|
| author | Yun Bai Gerile Aodeng Lu Ga Wenfeng Hai Jun Ai |
| author_facet | Yun Bai Gerile Aodeng Lu Ga Wenfeng Hai Jun Ai |
| author_sort | Yun Bai |
| collection | DOAJ |
| description | Cancer treatments, including traditional chemotherapy, have failed to cure human malignancies. The main reasons for the failure of these treatments are the inevitable drug resistance and serious side effects. In clinical treatment, only 5 percent of the 50 percent of cancer patients who are able to receive conventional chemotherapy survive. Because of these factors, being able to develop a drug and treatment that can target only cancer cells without affecting normal cells remains a big challenge. Since the special properties of cisplatin in the treatment of malignant tumors were accidentally discovered in the last century, metal anticancer drugs have become a research hotspot. Metal anticancer drugs have unique pharmaceutical properties, such as ruthenium metal drugs with their high selectivity, low toxicity, easy absorption by tumor tissue, excretion, and so on. In recent years, efficient and low-toxicity metal antitumor complexes have been synthesized. In this paper, the scientific literature on platinum (Pt), ruthenium (Ru), iridium (Ir), gold (Au), and other anticancer complexes was reviewed by referring to a large amount of relevant literature at home and abroad. |
| first_indexed | 2024-03-08T20:26:47Z |
| format | Article |
| id | doaj.art-361cfdaa8f37430ab23a1d10b9e6bde6 |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-03-08T20:26:47Z |
| publishDate | 2023-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-361cfdaa8f37430ab23a1d10b9e6bde62023-12-22T14:32:13ZengMDPI AGPharmaceutics1999-49232023-12-011512275010.3390/pharmaceutics15122750Research Progress of Metal Anticancer DrugsYun Bai0Gerile Aodeng1Lu Ga2Wenfeng Hai3Jun Ai4Inner Mongolia Key Laboratory of Environmental Chemistry, College of Chemistry and Enviromental Science, Inner Mongolia Normal University, 81 Zhaowudalu, Hohhot 010022, ChinaInner Mongolia Key Laboratory of Environmental Chemistry, College of Chemistry and Enviromental Science, Inner Mongolia Normal University, 81 Zhaowudalu, Hohhot 010022, ChinaCollege of Pharmacy, Inner Mongolia Medical University, Jinchuankaifaqu, Hohhot 010110, ChinaInner Mongolia Key Laboratory of Carbon Nanomaterials, Nano Innovation Institute (NII), College of Chemistry and Materials Science, Inner Mongolia Minzu University, Tongliao 028000, ChinaInner Mongolia Key Laboratory of Environmental Chemistry, College of Chemistry and Enviromental Science, Inner Mongolia Normal University, 81 Zhaowudalu, Hohhot 010022, ChinaCancer treatments, including traditional chemotherapy, have failed to cure human malignancies. The main reasons for the failure of these treatments are the inevitable drug resistance and serious side effects. In clinical treatment, only 5 percent of the 50 percent of cancer patients who are able to receive conventional chemotherapy survive. Because of these factors, being able to develop a drug and treatment that can target only cancer cells without affecting normal cells remains a big challenge. Since the special properties of cisplatin in the treatment of malignant tumors were accidentally discovered in the last century, metal anticancer drugs have become a research hotspot. Metal anticancer drugs have unique pharmaceutical properties, such as ruthenium metal drugs with their high selectivity, low toxicity, easy absorption by tumor tissue, excretion, and so on. In recent years, efficient and low-toxicity metal antitumor complexes have been synthesized. In this paper, the scientific literature on platinum (Pt), ruthenium (Ru), iridium (Ir), gold (Au), and other anticancer complexes was reviewed by referring to a large amount of relevant literature at home and abroad.https://www.mdpi.com/1999-4923/15/12/2750platinum anticancer drugsruthenium anticancer drugsiridium anticancer drugsgold anticancer drugscancer |
| spellingShingle | Yun Bai Gerile Aodeng Lu Ga Wenfeng Hai Jun Ai Research Progress of Metal Anticancer Drugs Pharmaceutics platinum anticancer drugs ruthenium anticancer drugs iridium anticancer drugs gold anticancer drugs cancer |
| title | Research Progress of Metal Anticancer Drugs |
| title_full | Research Progress of Metal Anticancer Drugs |
| title_fullStr | Research Progress of Metal Anticancer Drugs |
| title_full_unstemmed | Research Progress of Metal Anticancer Drugs |
| title_short | Research Progress of Metal Anticancer Drugs |
| title_sort | research progress of metal anticancer drugs |
| topic | platinum anticancer drugs ruthenium anticancer drugs iridium anticancer drugs gold anticancer drugs cancer |
| url | https://www.mdpi.com/1999-4923/15/12/2750 |
| work_keys_str_mv | AT yunbai researchprogressofmetalanticancerdrugs AT gerileaodeng researchprogressofmetalanticancerdrugs AT luga researchprogressofmetalanticancerdrugs AT wenfenghai researchprogressofmetalanticancerdrugs AT junai researchprogressofmetalanticancerdrugs |